Enzalutamide With Radiation Therapy for Intermediate-Risk Prostate Cancer: A Phase 2 Study

Journal Article · Sun Aug 15 04:00:00 EDT 2021 · International Journal of Radiation Oncology, Biology and Physics

DOI:https://doi.org/10.1016/J.IJROBP.2021.02.027· OSTI ID:23198486

Kaplan, Irving ^[1]; Bubley, Glenn J.; Bhatt, Rupal S. ^[1]; Taplin, Mary-Ellen ^[2]; Dowling, Shanna; Mahoney, Kathleen ^[1]; Werner, E. ^[3]; Nguyen, Paul ^[4]

---

1. Beth Israel Deaconess Medical Center, Harvard Medical School, Boston (United States)
2. Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston (United States)
3. Department of Biostatics, Dana-Farber Cancer Institute, Harvard Medical School, Boston (United States)
4. Department of Radiation Oncology, Brigham and Women’s Hospital, Harvard Medical School, Boston (United States)

Androgen deprivation therapy (ADT) is often used as adjuvant treatment with radiation therapy (RT) for intermediate-risk prostate cancer. ADT is associated with multiple side effects, including weight gain, loss of libido, and hot flashes. In contrast, antiandrogen monotherapy has been generally better tolerated. This study aimed to assess the effectiveness of enzalutamide (an antiandrogen) monotherapy with RT for the treatment of intermediate-risk prostate cancer.

• OSTI ID: 23198486
• Journal Information: International Journal of Radiation Oncology, Biology and Physics, Journal Name: International Journal of Radiation Oncology, Biology and Physics Journal Issue: 5 Vol. 110; ISSN IOBPD3; ISSN 0360-3016
• Country of Publication: United States
• Language: English

Related Subjects

62 RADIOLOGY AND NUCLEAR MEDICINE
ANDROGENS
ANTIANDROGENS
HEALTH HAZARDS
NEOPLASMS
PROSTATE
RADIOTHERAPY
SIDE EFFECTS